Uppsala, Sweden, 2013-06-07 08:59 CEST (GLOBE NEWSWIRE) --
Year-end report for the fiscal year May 2012 - April 2013 €
CONTINUED EXPANSION OF THE PRODUCT CANDIDATE PORTFOLIO AND STRATEGIC AGREEMENTS IN THE FISCAL YEAR
FOURTH QUARTER February 1 – April 30, 2013
- Consolidated Net sales amounted to € 0 thousand (0)[1]
- Operating income amounted to € -2,556 thousand (-2,265)
- Net income after tax amounted to € -2,677 thousand (-2,302)
- Earnings per share amounted to € -0.03 (-0.04)
- Comprehensive income amounted to € -2,677 thousand (-2,302)
- Oasmia and Pharmasyntez entered into a distribution agreement for Paclical® in Russia and CIS
THE FISCAL YEAR May 1, 2012 – April 30, 2013
- Consolidated Net sales amounted to € 0 thousand (104)
- Operating income amounted to € -7,881 thousand (-7,642)
- Net income after tax amounted to € -8,441 thousand (-7,658)
- Earnings per share amounted to € -0.12 (-0.14)
- Comprehensive income amounted to € -8,441 thousand (- 7,658)
EVENTS AFTER CLOSING DAY
-
Oasmia has developed the first pharmaceutical with two active cytostatics in one infusion, based on its patent protected XR-17 technology.
- Oasmia has initiated a clinical program for treatment of breast cancer with Paclical®
[1] The numbers in parentheses concern results from the corresponding period of the previous year
Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia
